Page 1,788«..1020..1,7871,7881,7891,790..1,8001,810..»

Wheelchair Kamikaze: Stem Cell Treatments for Multiple …

Posted: May 23, 2015 at 12:40 am

As all patients with MS are aware, the currently available treatments do nothing to cure the disease or repair the damage that it does. At their best, todays crop of disease modifying drugs (DMDs) quiet the disease, thereby improving the quality of life for many of the patients taking them, especially those suffering from relapsing remitting multiple sclerosis. However, many of these drugs carry with them risky side effect profiles, and though the newest compounds represent advances over their predecessors, patients are crying out for revolution, not evolution.

Stem cells could represent the revolution patients so fervently desire. Because of their ability to transform into almost any type of cell in the human body, stem cells may hold the key to achieving one of the holy grails of modern medicine, the regeneration and repair of damaged tissues. For MS patients, this could potentially mean the reversal of disability, and with it the long dreamt of disposal of wheelchairs, walkers, and canes. We are still a long way from that lofty goal, however, but the first few steps along the path to that salvation are currently being taken.

Though stem cell research is advancing in laboratories worldwide, the science of using stem cells to treat diseases in humans is still in its infancy. Because multiple sclerosis is a neurodegenerative disease, and its most prominent feature is the damage the disease does to the central nervous system, it is hoped that stem cells may hold the key to reversing the carnage wrought by the disease by facilitating the repair of damaged nerve cells. Furthermore, research has provided hints that stem cells may modulate the abnormal immune response seen in MS patients, and some researchers are even using stem cells to completely reboot the human immune system, a process that in some cases appears to stop the disease dead in its tracks.

Its important to understand that there are two very different approaches to using stem cells in the treatment of multiple sclerosis. One approach hopes to use the cells to repair damaged nervous systems; the other uses stem cells to provide the patient with a brand-new immune system, one that theoretically will not turn against a patients own body. The latter approach is known as hematopoietic stem cell transplant, or HSCT, and has been used on patients in trial settings for almost two decades.

HSCT involves ablating (destroying) a patients existing immune system through the use of powerful chemotherapy drugs, and then intravenously infusing a patients own stem cells back into their body, a process depicted in the below diagram:

As you might imagine, using powerful chemotherapy drugs to destroy a patients immune system is not without its dangers, and early attempts at this therapy had mortality rates as high as 10%. As researchers perfected their methodology and began using less dangerous chemotherapy agents, though, the risks associated with HSCT dropped dramatically. Today, most patients undergoing HSCT are subjected to chemotherapy and immunosuppressive agents that do not completely destroy their bone marrow, and the safety profile of the procedure has improved impressively. The results achieved by this HSCT can be dramatic. In one study (click here) that looked at the long-term outcomes of HSCT, after 11 years 44% of patients who had started out with aggressive relapsing remitting disease were free from disability progression. By comparison, only 10% of those who did not display signs of active inflammation before HSCT remained stable.

One of the primary proponents of HSCT therapy for MS patients, Dr. Richard Burt of Northwestern University, stresses that the proper selection of patients is the key to the success of the treatment. In fact, the title of the paper he recently published (click here) includes the phrase if no inflammation, no response. Its the only therapy to date that has been shown to reverse neurologic deficits, said Dr. Burt, But you have to get the right group of patients. In a study published by Dr. Burt in 2009, 17 out of 21 relapsing remitting patients improved after HSCT, and after three years all patients were free from progression (click here). Dr. Burt is currently heading up the HALT-MS trial for HSCT (click here). There are several centers around the world offering HSCT therapy, and there is a Worldwide HSCT Facebook group (click here) that contains information on all of the legitimate HSCT facilities worldwide. The group is populated by many folks who have undergone HSCT therapy. Be aware that its a private group, and you must request membership before being given access to all of the available information.

While HSCT holds much promise for putting the brakes on very aggressive relapsing remitting multiple sclerosis, it unfortunately has little to offer those with progressive disease, and does nothing to directly repair the damage done to the central nervous system by MS. Fortunately, another form of stem cell therapy proposes to do just that. Researchers in two centers in the US have received FDA approval to use bone marrow derived mesenchymal stem cells (MSCs) to repair nervous system damage, thereby possibly reversing the effects of the disease. There are additional trials using MSCs to treat MS underway internationally. Mesenchymal stem cells have the ability to transform (differentiate) into many different cell types, and could prove to be the building blocks necessary for repairing damage to the central nervous system as well as other organs and tissues. Experiments using MSCs to treat animal models of MS have been very encouraging (click here), demonstrating the cells abilities to modulate the immune system and spur the repair of damaged nervous system tissues. It remains to be seen whether the same effects can be achieved when using the cells to treat human beings.

The two FDA approved studies both use MSCs harvested from a patients own bone marrow, but employ them in very different ways. One study, currently underway at the Cleveland Clinic (click here), infuses mesenchymal stem cells intravenously into the patient, in the expectation that the cells will modulate the immune system and also initiate the regeneration of damaged tissues in the central nervous system. This study, which will eventually use MSCs to treat 24 patients, is proceeding slowly, but as the above linked to article details, one of the first patients treated is already reporting encouraging results.

The second FDA approved trial, to be conducted by the Tisch MS Research Center of New York (which just so happens to be my MS clinic), will use mesenchymal stem cells that have been transformed through a proprietary laboratory process into neural progenitor (NP) cells, injected directly into the spinal fluid (intrathecally)) of the patient (click here). Neural progenitor cells are a specialized type of stem cell specific to the nervous system that have the ability to transform into the various types of tissues damaged and destroyed by the MS disease process. Researchers at the Tisch Center have developed a way to get mesenchymal stem cells to differentiate into neural progenitor cells, and hope that by injecting these cells directly into the spinal fluid the NP cells will directly target the regenerative mechanisms of the central nervous system (click here). The stem cells themselves may act to repair damaged tissues, but theyve also been shown to have the ability to recruit existing stem cells within the brain and spinal cord to jumpstart the bodys own repair mechanisms.

Go here to see the original:
Wheelchair Kamikaze: Stem Cell Treatments for Multiple ...

Posted in Stem Cell Treatments | Comments Off on Wheelchair Kamikaze: Stem Cell Treatments for Multiple …

Stem Cells Adult Stem Cells & Stem Cell Treatments …

Posted: May 23, 2015 at 12:40 am

Click Here for Full Article

1 Stem Cell Treatments can help you today! Stem cells can actually help with a variety of conditions like Cerebral Palsy, ALS, Parkinsons, Stroke, TBI and more! read more.

2 Bone Marrow Stem Cells can be used as a safe & effective treatment for degenerative diseases. Dr. Steenblock has successfully performed/consulted on over 3,000 bone marrow stem cell therapy cases. read more

3Stemgevity was developed by physician Dr. David Steenblock to help mobilize your bodys own stem cells. Stemgevity is an all natural supplement that can help you start healing todayread more

4 In this revolutionizing book, both Dr. Steenblock & Dr. Payne describe the benefits of healthy umbilical cord stem cells and their ability to treat conditions like Cerebral Palsy.read more

The use of fat stem cells is not without risk, something brought into sharp focus late last year (2012) when stories surfaced in the media concerning a lady in Los Angeles who had a cosmetic procedure in which mesenchymal stem cells isolated from her own harvested fat were injected around her eyes along with a FDA approved dermal filler used to reduce wrinkles. The dermal filler contained calcium hydroxylapatite Read More

To hear critics of complementary alternative medicine (CAM) tell it, wholistic doctors such as myself are having a pervasive and insidious influence not only among medical consumers (aka the public) but weve managed to thoroughly infiltrate academia and hospitals and as a result are poised to catapult medicine back into the prescientific Middle Ages. If you compare the language and reasoning of many modern day quackbusters and so-called skeptics alongside newspaper articles from the 1950s McCarthy era Read More

DISCLAIMER: The use of stem cells or stem cell rich tissues as well as the mobilization of stem cells by any means, e.g., pharmaceutical, mechanical or herbal-nutrient is not FDA approved to combat aging or to prevent, treat, cure or mitigate any disease or medical condition mentioned, cited or described in any document or article on this website. This website and the information featured, showcased or otherwise appearing on it is not to be used as a substitute for medical advice, diagnosis or treatment of any health condition or problem. Those who visit this web site should not rely on information provided on it for their own health problems. Any questions regarding your own health should be addressed to your physician or other duly licensed healthcare provider. This website makes no guarantees, warranties or express or implied representations whatsoever with regard to the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced on this Web site. This website and its owners and operators do not assume any risk whatsoever for your use of this website or the information posted herein. Health-related information and opinions change frequently and therefore information contained on this Website may be outdated, incomplete or incorrect. All statements made about products, drugs and such on this website have not been evaluated by the Food and Drug Administration (FDA). In addition, any testimonials appearing on this website are based on the experiences of a few people and you are not likely to have similar results. Use of this Website does not create an expressed or implied professional relationship.

See the article here:
Stem Cells Adult Stem Cells & Stem Cell Treatments ...

Posted in Stem Cell Treatments | Comments Off on Stem Cells Adult Stem Cells & Stem Cell Treatments …

Stem cell – Wikipedia, the free encyclopedia

Posted: May 23, 2015 at 12:40 am

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cellsectoderm, endoderm and mesoderm (see induced pluripotent stem cells)but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

There are three known accessible sources of autologous adult stem cells in humans:

Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's own body, just as one may bank his or her own blood for elective surgical procedures.

Adult stem cells are frequently used in medical therapies, for example in bone marrow transplantation. Stem cells can now be artificially grown and transformed (differentiated) into specialized cell types with characteristics consistent with cells of various tissues such as muscles or nerves. Embryonic cell lines and autologous embryonic stem cells generated through Somatic-cell nuclear transfer or dedifferentiation have also been proposed as promising candidates for future therapies.[1] Research into stem cells grew out of findings by Ernest A. McCulloch and James E. Till at the University of Toronto in the 1960s.[2][3]

The classical definition of a stem cell requires that it possess two properties:

Two mechanisms exist to ensure that a stem cell population is maintained:

Potency specifies the differentiation potential (the potential to differentiate into different cell types) of the stem cell.[4]

In practice, stem cells are identified by whether they can regenerate tissue. For example, the defining test for bone marrow or hematopoietic stem cells (HSCs) is the ability to transplant the cells and save an individual without HSCs. This demonstrates that the cells can produce new blood cells over a long term. It should also be possible to isolate stem cells from the transplanted individual, which can themselves be transplanted into another individual without HSCs, demonstrating that the stem cell was able to self-renew.

Properties of stem cells can be illustrated in vitro, using methods such as clonogenic assays, in which single cells are assessed for their ability to differentiate and self-renew.[7][8] Stem cells can also be isolated by their possession of a distinctive set of cell surface markers. However, in vitro culture conditions can alter the behavior of cells, making it unclear whether the cells will behave in a similar manner in vivo. There is considerable debate as to whether some proposed adult cell populations are truly stem cells.

Embryonic stem (ES) cells are stem cells derived from the inner cell mass of a blastocyst, an early-stage embryo.[9] Human embryos reach the blastocyst stage 45 days post fertilization, at which time they consist of 50150 cells. ES cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In other words, they can develop into each of the more than 200 cell types of the adult body when given sufficient and necessary stimulation for a specific cell type. They do not contribute to the extra-embryonic membranes or the placenta.

More here:
Stem cell - Wikipedia, the free encyclopedia

Posted in Stem Cell Research | Comments Off on Stem cell – Wikipedia, the free encyclopedia

The Stem Cell Debate: Is it over? – Learn Genetics

Posted: May 23, 2015 at 12:40 am

HOME

Stem Cells

The Stem Cell Debate: Is It Over?

Stem cell therapies are not new. Doctors have been performing bone marrow stem cell transplants for decades. But when scientists learned how to remove stem cells from human embryos in 1998, both excitement and controversy ensued.

The excitement was due to the huge potential these cells have in curing human disease. The controversy centered on the moral implications of destroying human embryos. Political leaders began to debate over how to regulate and fund research involving human embryonic stem (hES) cells.

Newer breakthroughs may bring this debate to an end. In 2006 scientists learned how to stimulate a patient's own cells to behave like embryonic stem cells. These cells are reducing the need for human embryos in research and opening up exciting new possibilities for stem cell therapies.

Both human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells are pluripotent: they can become any type of cell in the body. While hES cells are isolated from an embryo, iPS cells can be made from adult cells.

Until recently, the only way to get pluripotent stem cells for research was to remove the inner cell mass of an embryo and put it in a dish. The thought of destroying a human embryo can be unsettling, even if it is only five days old.

Stem cell research thus raised difficult questions:

With alternatives to hES cells now available, the debate over stem cell research is becoming increasingly irrelevant. But ethical questions regarding hES cells may not entirely go away.

Excerpt from:
The Stem Cell Debate: Is it over? - Learn Genetics

Posted in Stem Cell Research | Comments Off on The Stem Cell Debate: Is it over? – Learn Genetics

Testosterone Replacement Therapy – Werner, MD

Posted: May 21, 2015 at 11:54 pm

If you have low testosterone levels or andropause an often effective solution is Testosterone replacement therapy. There are similar testosterone replacement treatments available for women.

What kind of goals can you hope to achieve with testosterone replacement therapy? They include the restoration of sexual functioning, increased libido, increased sense of well-being, prevention of osteoporosis by optimizing bone density, restoration of muscle strength, and improved mental functioning. Biochemically, testosterone replacement should aim not only to reach normal levels of serum testosterone, but also to normalize levels of those secondary hormones that are affected by testosterone levels such as DHT and estradiol.

Current treatment options include oral tablets or capsules, injections, plantable long-acting slow release pellets, and transdermal (through the skin) patches and gels. At this point, the vast majority of testosterone replacement is done through the skin. This method has a number of advantages:

Download Testosterone Replacement Therapy / Andropause Info Packet

To learn more about testosterone therapy, please call Dr. Werner's office at (914) 997-4100 or (203) 831-9900 or send us an email at info@wernermd.com.

Read more here:
Testosterone Replacement Therapy - Werner, MD

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy – Werner, MD

What is Integrative Medicine and Health? | Osher Center …

Posted: May 21, 2015 at 8:42 pm

What is Integrative Medicine and Health?

Integrative medicine and health reaffirm the importance of the relationship between practitioner and patient, focuses on the whole person, is informed by evidence, and makes use of all appropriate therapeutic approaches, healthcare professionals and disciplines to achieve optimal health and healing.

Integrative medicine combines modern medicine with established approaches from around the world. By joining modern medicine with proven practices from other healing traditions, integrative practitioners are better able to relieve suffering, reduce stress, maintain the well-being, and enhance the resilience of their patients.

Although the culture of biomedicine is predominant in the U.S., it coexists with many other healing traditions. Many of these approaches have their roots in non-Western cultures. Others have developed within the West, but outside what is considered conventional medical practice.

Various terms have been used to describe the broad range of healing approaches that are not widely taught in medical schools, generally available in hospitals or routinely reimbursed by medical insurance.

Complementary and alternative medicine (CAM) is the name chosen by the National Institutes of Health. CAM is defined as the broad range of healing philosophies, approaches, and therapies that mainstream Western (conventional) medicine does not commonly use, accept, study, understand, or make available. CAM therapies may be used alone, as an alternative to conventional therapies, or in addition to conventional, mainstream medicine to treat conditions and promote well-being.

Integrative medicine is a new term that emphasizes the combination of both conventional and alternative approaches to address the biological, psychological, social and spiritual aspects of health and illness. It emphasizes respect for the human capacity for healing, the importance of the relationship between the practitioner and the patient, a collaborative approach to patient care among practitioners, and the practice of conventional, complementary, and alternative health care that is evidence-based.

According to the 2012 National Health Interview Survey:

Read the 2012 report What Complementary and Integrative Approaches Do Americans Use?

CAM is attractive to many people because of its emphasis on treating the whole person, its promotion of good health and well-being, its valuing of prevention, and its often more personalized approach to patient concerns.

Read the original:
What is Integrative Medicine and Health? | Osher Center ...

Posted in Integrative Medicine | Comments Off on What is Integrative Medicine and Health? | Osher Center …

First Stroke Patient Treated With Neural Stem Cell Therapy

Posted: May 20, 2015 at 4:49 pm

The first patient in the landmark Pilot Investigation of Stem Cells in Stroke (PISCES) trial has been treated with neural stem cells. The study is the first fully regulated clinical trial of neural stem cell therapy for stroke. Investigators will evaluate the safety of ReNeuron cells in disabled ischemic stroke patients.

This is a first in man safety study, lead investigator Keith Muir, MD, from the University of Glasgows Institute of Neuroscience and Psychology in Scotland, explained to Medscape Medical News. We are looking at neurological effects clinical and imaging only as secondary goals.

The stem cells are from a genetically modified immortalized cell line derived from a tissue sample from 12-week fetal cortex.

Critics of stem cell development generally have various reasons for their ethical objections, Dr. Muir said. For most, it relates to embryo use not relevant in this case, he argues. Others might object to termination of pregnancy, but these cells are derived from material donated to a tissue bank from a single legal termination many years ago, which was done for social reasons and was unrelated to the subsequent use.

This study was approved by the United Kingdom Medicines and Healthcare Products Regulatory Agency. ReNeuron is the first company to receive regulatory approval for any stem cellbased clinical trial in the United Kingdom.

PISCES Trial

The first patient in this pilot investigation was treated in Glasgow. The male patient was injected with cells to the affected region of the brain and has since been discharged from the hospital. He will be monitored closely for 2 years with longer-term follow-up procedures afterward.

Investigators are still recruiting for the trial and plan for 12 patients to take part. They will be given the ReN001 therapy between 6 and 24 months after stroke.

PISCES is an open-label study with no control group. We feel this is an appropriate design for a first in man study, Dr. Muir said, and we are not seeking to draw conclusions about efficacy at this stage.

Trial investigators suggest that because of the nature of the procedure and the characteristics of the stem cells, immunosuppression will not be necessary for patients taking part in the study. This, they say, will eliminate the safety risks typically associated with immunosuppression regimens.

Continue reading here:
First Stroke Patient Treated With Neural Stem Cell Therapy

Posted in Vermont Stem Cells | Comments Off on First Stroke Patient Treated With Neural Stem Cell Therapy

Main Navigation

Posted: May 20, 2015 at 4:43 pm

Welcome to the webpage for The Arizona Stem Cell Center.

We are the first and original facility offering autologous stem cell transplants derived from adipose tissue in Arizona.

Our unique and innovative process allows us to extract several million stem cells from a single fat biopsy. Our extraction technique involves minimal handling of the cells and same day transplantation. Using a patient's own tissue as the source for cells minimizes rejection of the transplanted tissues, potentially maximizing the effectiveness of the transplant.

Here at Total Wellness/AZ Stem Cell Center, we have been using the technique of PRP (Platelet Rich Plasma) for the past decade for musculoskeletal injuries, autoimmune conditions like Lupus and Multiple Sclerosis, degenerative conditions like osteoarthritis, Parkinson's Syndrome and ALS (Amyotrophic Lateral Sclerosis) and chronic viral conditions (including Epstein-Barr, Cytomegalovirus and Herpes viruses). This is an incredibly versatile therapy that has its roots in the eclectic European medical armamentarium of the 1930's.

Platelet rich plasma can be employed as a matrix graft, often referred to as an autologous tissue graft. This platelet-rich plasma (PRP) matrix is defined as a "tissue graft incorporating autologous growth factors and/or autologous undifferentiated cells in a cellular matrix where design depends on the receptor site and tissue of regeneration." (Crane D, Everts PAM. Practical Pain Management. 2008; January/February: 12- 26) 2008). We enrich the autologous tissue graft with hyaluronic acid for stem cell transplants.

The hypothesized reason why PRP with hyaluronic acid is so useful in autologous tissue grafts with stem cells is that platelets, a normal blood cell that aids in clotting, contain multiple growth factors that stimulate tissue growth. In particular, PRP stimulates the growth of collagen; the main component of connective tissue such as tendons and cartilage. These growth factors include transforming growth factor-? (TGF-B), fibroblast growth factor, platelet-derived growth factor, epidermal growth factor, connective tissue growth factor, and vascular endothelial growth factor.

These growth factors normally recruit undifferentiated stem cells to the site of injury and stimulate new tissue growth. Another constituent of platelets, stromal cell derived factor I alpha allows the newly recruited cells to adhere to the area. Hyaluronic acid is a nutritionally supportive polysaccharide substrate for stem cells that is found abundantly in embryonic tissue. When stem cells are harvested from the patient's own tissues, PRP helps to activate the stem cells to actively become a desired tissue line and Hyaluronic Acid helps support.

In addition, when used with stem cells harvested from the patient's own tissue, PRP messages the stem cells to multiply quickly. This inflammatory response is a major driver of appropriate healing response.

An important consideration is that PRP needs to be prepared in a way to ensure a maximal amount of platelets along with a high concentration of growth factors. Obviously, the more growth factors that can be delivered to the site of injury, the more likely tissue healing takes place. We have found that creating a matrix of Hyaluronic acid (a base connective tissue material) with the PRP and the addition of other growth factors can tremendously expedite the healing process. We are the only clinic in the world to integrate stem cell transplantation with PRP.

Neither Statements, nor products on this site, have been evaluated nor approved by the FDA. Total Wellness offers autologous stem cell treatments. These are not approved treatments, drugs, new drugs, or investigational drugs. We do not manufacture products. If you have concern with a treatment or product that we perform or produce, and think we may be violating any USA law, please contact us immediately, so that our legal team can investigate the matter or concern. All statements, opinions, and advice provided by this website, via wire, or by educational seminars, is provided for educational information only. We do not diagnose nor treat via this website or phone. We offer the above therapies via a doctor/patient established relationship which requires direct contact with the physician. Again, visitors should be aware that we are not claiming that any applications, or potential applications using these autologous treatments, are approved by the FDA, or are even effective. We do not claim that these treatments work for any listed nor unlisted condition, intended or implied.

Here is the original post:
Main Navigation

Posted in Arizona Stem Cells | Comments Off on Main Navigation

Development of the retina and optic pathway – ScienceDirect

Posted: May 20, 2015 at 1:43 pm

Abstract

Our understanding of the development of the retina and visual pathways has seen enormous advances during the past 25years. New imaging technologies, coupled with advances in molecular biology, have permitted a fuller appreciation of the histotypical events associated with proliferation, fate determination, migration, differentiation, pathway navigation, target innervation, synaptogenesis and cell death, and in many instances, in understanding the genetic, molecular, cellular and activity-dependent mechanisms underlying those developmental changes. The present review considers those advances associated with the lineal relationships between retinal nerve cells, the production of retinal nerve cell diversity, the migration, patterning and differentiation of different types of retinal nerve cells, the determinants of the decussation pattern at the optic chiasm, the formation of the retinotopic map, and the establishment of ocular domains within the thalamus.

In 1986, when Vision Research published its 25th Anniversary Issue, there was no chapter dedicated to developmental visual anatomy, being the summary descriptor provided by the editors for the present chapter. The closest coverage was provided within a chapter on visual development, focusing upon the acquisition of visual function, the consequences of early visual deprivation or restricted visual exposure, and on the associated plasticity within visual cortex ( Teller & Movshon, 1986). It is interesting to re-visit that historical overview now, 25years later, to appreciate the excitement within the field during those golden years of visual neurophysiology. Three pioneers in our understanding of the development of the visual system received the Nobel Prize in Physiology or Medicine during that era, in 1981, Roger Sperry, David Hubel and Torsten Wiesel, and the contributions of two of them feature prominently within that article. As acknowledged by the authors, In 1960, the neurobiology of visual development was dominated by the work of Roger Sperry. But rather than this being the prelude to a tribute, Sperry is taken to task for his preoccupation with the hard-wiring of the visual pathway, and his impact for the era under review was largely dismissed: Sperrys relentless emphasis on the independence of neural development from neural function in the developing animal was to have a short life after 1961 (p. 1486, original italics).

Since that anniversary issue in 1986, the past 25years have witnessed unprecedented experimental as well as conceptual advances in our understanding of the development of the retina and sub-cortical visual pathways, much of it occurring well before the onset of visual function. Many of these advances vindicate a hard-wiring perspective such as Sperrys, relying upon cell-signaling interactions independent of neural transmission, while others show that neural function long before the onset of photo-transduction plays a critical role in the formation of neural circuitry. The phenomenal scientific pace of the past 25years has been made possible largely by new technologies that continue to expand the front of developmental neurobiology in general. The experimental advances have been a consequence of the revolution in molecular biology and by the availability of new imaging technologies, permitting genetic dissection of the molecular factors and cellular interactions underlying retinal and optic pathway development, and the visualization of single neurons or populations of cells as they pass through the cell cycle, express transcription factors and the downstream genes they regulate, migrate to their specific layers, differentiate their characteristic morphologies, navigate an axonal trajectory to central visual structures, establish and refine their synaptic connections, and undergo programmed cell death. The present review will not consider in detail those technical advances themselves; the reader is directed to another recent colorful review providing ample coverage of this ever-expanding toolbox (Mason, 2009). The consequent experimental results have led to new conceptual insights, altering the ways in which we think about retinal development and target innervation, and the present focus will be upon these changes in our understanding.

One should not fault the myopia of the former review too much; without a doubt, we simply could not appreciate the full nature of the neurobiological issues at play 25years ago.1 Visual cortex was where the action was, and electrophysiology was the tool of choice for understanding the mechanics underlying visual function. We now know so much more about the pre-visual development of the retina and sub-cortical visual pathways, from a decidedly cellular and molecular biological perspective, that I will restrict the present coverage accordingly, and unashamedly, as vision will hardly be mentioned.

By comparison with the other chapters in this special issue of Vision Research, the purview of the present chapter is vast, encompassing advances not only in our understanding of the various components establishing the complex architecture and connectivity of the neural retina, but also of the visual pathways and their innervation of target visual structures. Any such review of strides taken over a defined period of time must to some extent be idiosyncratic (as in that former paper), but I believe these issues largely summarize the major conceptual and experimental advances during the past 25years. I have chosen to highlight eight issues, briefly recapitulating these advances and sacrificing much detail due to space limitations. Each of these topics has been reviewed in far greater detail elsewhere, and doubtless researchers working on development of the visual system will find reason enough to feel frustrated by the brevity of the present effort. Rather, my intended audience has been that collection of vision researchers that digest the literature on retinal and pathway development with only modest fervor, to give them a synopsis of the major advances during this era, as well as current students and post-docs working within this field of developmental neurobiology that may not appreciate the degree to which this field has advanced. The latter group need only compare the coverage of the developing retina and visual pathway provided by textbooks then in use (e.g. Jacobson, 1978andPurves and Lichtman, 1985) with that provided more recently ( Sanes, Reh, & Harris, 2006) to appreciate the remarkable evolution in our understanding of these developmental processes. The former textbooks reflect the strong foundations of the field drawn from experimental embryology and neurophysiology but now seem sadly deficient in providing much account of the histotypical interactions between cells or of the genes expressed and molecular signals they set in motion that participate in these events.

Twenty-five years ago, while we had some appreciation that an early eye field was derived from the neural plate and was critical for the development of the retina, we had no knowledge of the transcriptional control of this process by a handful of early eye-field genes that are now understood to command a downstream cascade of genes critical for assembling the mature retina (Zuber & Harris, 2006). As the eye cup emerges and expands in size, the factors modulating cell cycle kinetics have been dissected with increasing detail, including the molecular mechanisms driving interkinetic nuclear translocation, the intracellular and extracellular determinants of cell-cycle exit, and the factors that coordinate the wave of neurogenesis progressing from its site of initiation (Agathocleous and Harris, 2009, Baye and Link, 2007, Del Bene et al., 2008, Dyer and Cepko, 2001, Levine and Green, 2004, Martins and Pearson, 2008andNorden et al., 2009). The present coverage will begin with the emerging neural retina at the outset of neurogenesis, considering advances in our understanding of the lineage relationships between retinal neurons, the determination of neuronal cell-types and the production of species-specific retinal architecture, the control of neuronal positioning, and the determinants of morphological differentiation.

Retinal progenitors were understood to expand the pool of post-mitotic precursor cells that would ultimately adopt various cellular fates, but there was no firm understanding of whether dedicated progenitors yielded particular types of cell, or if progenitors were multi-potent. While birth-dating studies had already shown that each type of retinal nerve cell was born in a distinct window during retinal neurogenesis (Carter-Dawson and LaVail, 1979, Drger, 1985, Hinds and Hinds, 1979, Sidman, 1961andYoung, 1985), these provided no insight into the clonal relationships between the cells of the retina. In the late 1980s, two different approaches were employed to label single retinal progenitor cells in order to identify their progeny at subsequent stages of maturity. One was to inject single cells with cytoplasmic tracers that would remain detectable within progeny despite progressive dilution following repeated cell divisions (Holt et al., 1988andWetts and Fraser, 1988). The other was to use replication-deficient retroviruses encoding reporter genes to infect single cells, therein bypassing the problem of progressive dilution with repeated mitoses (Turner and Cepko, 1987andTurner et al., 1990). Both approaches yielded comparable findings that retinal progenitor cells were in fact multi-potent, producing clones of cells that included a variety of retinal neuronal types as well as Mller glia. They lacked, however, any retinal astrocytes, handily accounted for, at roughly the same time, by the demonstration that astrocytes are immigrants to the neural retina, being derived from a distinct progenitor cell in the optic stalk and migrating into the inner retina during the period of retinal neurogenesis (Ling and Stone, 1988, Stone and Dreher, 1987andWatanabe and Raff, 1988).

See original here:
Development of the retina and optic pathway - ScienceDirect

Posted in Stell Cell Genetics | Comments Off on Development of the retina and optic pathway – ScienceDirect

JAX Mice Database – 010636 NOD.Cg-B2m Prkdc

Posted: May 20, 2015 at 1:43 pm

B2mtm1Unc related

Adoro S; Erman B; Sarafova SD; Van Laethem F; Park JH; Feigenbaum L; Singer A. 2008. Targeting CD4 coreceptor expression to postselection thymocytes reveals that CD4/CD8 lineage choice is neither error-prone nor stochastic. J Immunol 181(10):6975-83. [PubMed: 18981117] [MGI Ref ID J:140942]

Adoro S; McCaughtry T; Erman B; Alag A; Van Laethem F; Park JH; Tai X; Kimura M; Wang L; Grinberg A; Kubo M; Bosselut R; Love P; Singer A. 2011. Coreceptor gene imprinting governs thymocyte lineage fate. EMBO J 31(2):366-77. [PubMed: 22036949] [MGI Ref ID J:180236]

Agerstam H; Jaras M; Andersson A; Johnels P; Hansen N; Lassen C; Rissler M; Gisselsson D; Olofsson T; Richter J; Fan X; Ehinger M; Fioretos T. 2010. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood 116(12):2103-11. [PubMed: 20554971] [MGI Ref ID J:164507]

Aguado E; Richelme S; Nunez-Cruz S; Miazek A; Mura AM; Richelme M; Guo XJ; Sainty D; He HT; Malissen B; Malissen M. 2002. Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science 296(5575):2036-40. [PubMed: 12065839] [MGI Ref ID J:77098]

Albu DI; Vanvalkenburgh J; Morin N; Califano D; Jenkins NA; Copeland NG; Liu P; Avram D. 2011. Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes. Proc Natl Acad Sci U S A 108(15):6211-6. [PubMed: 21444811] [MGI Ref ID J:171277]

Aldrich CJ; Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Forman J. 1994. Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice. Proc Natl Acad Sci U S A 91(14):6525-8. [PubMed: 8022816] [MGI Ref ID J:19192]

Alli R; Nguyen P; Boyd K; Sundberg JP; Geiger TL. 2012. A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J Immunol 188(1):477-86. [PubMed: 22116824] [MGI Ref ID J:180590]

Alsharifi M; Lobigs M; Simon MM; Kersten A; Muller K; Koskinen A; Lee E; Mullbacher A. 2006. NK cell-mediated immunopathology during an acute viral infection of the CNS. Eur J Immunol 36(4):887-96. [PubMed: 16541469] [MGI Ref ID J:114787]

Antal Z; Baker JC; Smith C; Jarchum I; Babad J; Mukherjee G; Yang Y; Sidney J; Sette A; Santamaria P; DiLorenzo TP. 2012. Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes. J Immunol 188(11):5766-75. [PubMed: 22539795] [MGI Ref ID J:188404]

Visit link:
JAX Mice Database - 010636 NOD.Cg-B2m Prkdc

Posted in Stell Cell Genetics | Comments Off on JAX Mice Database – 010636 NOD.Cg-B2m Prkdc

Page 1,788«..1020..1,7871,7881,7891,790..1,8001,810..»